Literature DB >> 22695718

Casein kinase 2α regulates multidrug resistance-associated protein 1 function via phosphorylation of Thr249.

Elzbieta I Stolarczyk1, Cassandra J Reiling, Kerry A Pickin, Ryan Coppage, Marc R Knecht, Christian M Paumi.   

Abstract

We have shown previously that the function of Ycf1p, yeast ortholog of multidrug resistance-associated protein 1 (MRP1), is regulated by yeast casein kinase 2α (Cka1p) via phosphorylation at Ser251. In this study, we explored whether casein kinase 2α (CK2α), the human homolog of Cka1p, regulates MRP1 by phosphorylation at the semiconserved site Thr249. Knockdown of CK2α in MCF7-derived cells expressing MRP1 [MRP1 CK2α(-)] resulted in increased doxorubicin sensitivity. MRP1-dependent transport of leukotriene C(4) and estradiol-17β-d-glucuronide into vesicles derived from MRP1 CK2α(-) cells was decreased compared with MRP1 vesicles. Moreover, mutation of Thr249 to alanine (MRP1-T249A) also resulted in decreased MRP1-dependent transport, whereas a phosphomimicking mutation (MRP1-T249E) led to dramatic increase in MRP1-dependent transport. Studies in tissue culture confirmed these findings, showing increased intracellular doxorubicin accumulation in MRP1 CK2α(-) and MRP1-T249A cells compared with MRP1 cells. Inhibition of CK2 kinase by 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole resulted in increased doxorubicin accumulation in MRP1 cells, but not in MRP1 CK2α(-), MRP1-T249A, or MRP1-T249E cells, suggesting that CK2α regulates MRP1 function via phosphorylation of Thr249. Indeed, CK2α and MRP1 interact physically, and recombinant CK2 phosphorylates MRP1-derived peptide in vitro in a Thr249-dependent manner, whereas knockdown of CK2α results in decreased phosphorylation at MRP1-Thr249. The role of CK2 in regulating MRP1 was confirmed in other cancer cell lines where CK2 inhibition decreased MRP1-mediated efflux of doxorubicin and increased doxorubicin cytotoxicity. This study supports a model in which CK2α potentiates MRP1 function via direct phosphorylation of Thr249.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22695718      PMCID: PMC3422697          DOI: 10.1124/mol.112.078295

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  49 in total

1.  The enzymatic phosphorylation of proteins.

Authors:  G BURNETT; E P KENNEDY
Journal:  J Biol Chem       Date:  1954-12       Impact factor: 5.157

2.  CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation.

Authors:  Kazuhiko Yamane; Timothy J Kinsella
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

3.  Large-scale phosphorylation analysis of mouse liver.

Authors:  Judit Villén; Sean A Beausoleil; Scott A Gerber; Steven P Gygi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-22       Impact factor: 11.205

4.  Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2.

Authors:  S Mishra; V Pertz; B Zhang; P Kaur; H Shimada; J Groffen; Z Kazimierczuk; L A Pinna; N Heisterkamp
Journal:  Leukemia       Date:  2006-11-02       Impact factor: 11.528

Review 5.  Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.

Authors:  James S Duncan; David W Litchfield
Journal:  Biochim Biophys Acta       Date:  2007-08-30

6.  Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.

Authors:  G Di Maira; F Brustolon; J Bertacchini; K Tosoni; S Marmiroli; L A Pinna; M Ruzzene
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

7.  Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP1.

Authors:  Youyun Yang; Yang Liu; Zizheng Dong; Junkang Xu; Hui Peng; Zhaoqian Liu; Jian-Ting Zhang
Journal:  J Biol Chem       Date:  2007-01-30       Impact factor: 5.157

8.  Gene targeting of CK2 catalytic subunits.

Authors:  David C Seldin; David Y Lou; Paul Toselli; Esther Landesman-Bollag; Isabel Dominguez
Journal:  Mol Cell Biochem       Date:  2008-07-02       Impact factor: 3.396

9.  Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites.

Authors:  A A Kramerov; M Saghizadeh; S Caballero; L C Shaw; S Li Calzi; M Bretner; M Montenarh; L A Pinna; M B Grant; A V Ljubimov
Journal:  Mol Cell Biochem       Date:  2008-07-09       Impact factor: 3.396

Review 10.  Role of the MRP1/ABCC1 multidrug transporter protein in cancer.

Authors:  Marcia Munoz; Michelle Henderson; Michelle Haber; Murray Norris
Journal:  IUBMB Life       Date:  2007-12       Impact factor: 3.885

View more
  10 in total

1.  Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90β as a Novel Mechanism of Rifampin-induced MDR1 Expression.

Authors:  So Won Kim; Md Hasanuzzaman; Munju Cho; Ye Rang Heo; Min-Jung Ryu; Na-Young Ha; Hyun June Park; Hyung-Yeon Park; Jae-Gook Shin
Journal:  J Biol Chem       Date:  2015-05-20       Impact factor: 5.157

2.  Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential.

Authors:  Giorgio Cozza; Cristina Girardi; Alessandro Ranchio; Graziano Lolli; Stefania Sarno; Andrzej Orzeszko; Zygmunt Kazimierczuk; Roberto Battistutta; Maria Ruzzene; Lorenzo A Pinna
Journal:  Cell Mol Life Sci       Date:  2014-01-18       Impact factor: 9.261

Review 3.  Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions.

Authors:  Rebecca R Crawford; Praveen K Potukuchi; Erin G Schuetz; John D Schuetz
Journal:  Drug Metab Dispos       Date:  2018-03-07       Impact factor: 3.922

Review 4.  Post-translational modifications of transporters.

Authors:  Lindsay C Czuba; Kathleen M Hillgren; Peter W Swaan
Journal:  Pharmacol Ther       Date:  2018-06-30       Impact factor: 12.310

5.  Structure of Ycf1p reveals the transmembrane domain TMD0 and the regulatory region of ABCC transporters.

Authors:  Sarah C Bickers; Samir Benlekbir; John L Rubinstein; Voula Kanelis
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 11.205

6.  Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.

Authors:  Sofia Zanin; Christian Borgo; Cristina Girardi; Sean E O'Brien; Yoshihiko Miyata; Lorenzo A Pinna; Arianna Donella-Deana; Maria Ruzzene
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

Review 7.  Leukemia and ABC transporters.

Authors:  Yu Fukuda; Shangli Lian; John D Schuetz
Journal:  Adv Cancer Res       Date:  2015-01-08       Impact factor: 5.767

8.  Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance.

Authors:  Amin Emad; Junmei Cairns; Krishna R Kalari; Liewei Wang; Saurabh Sinha
Journal:  Genome Biol       Date:  2017-08-11       Impact factor: 13.583

9.  Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.

Authors:  Katsutoshi Sato; Amol A Padgaonkar; Stacey J Baker; Stephen C Cosenza; Olga Rechkoblit; D R C Venkata Subbaiah; Josep Domingo-Domenech; Alison Bartkowski; Elisa R Port; Aneel K Aggarwal; M V Ramana Reddy; Hanna Y Irie; E Premkumar Reddy
Journal:  Nat Commun       Date:  2021-08-03       Impact factor: 14.919

10.  The structural basis for regulation of the glutathione transporter Ycf1 by regulatory domain phosphorylation.

Authors:  Nitesh Kumar Khandelwal; Cinthia R Millan; Samantha I Zangari; Samantha Avila; Dewight Williams; Tarjani M Thaker; Thomas M Tomasiak
Journal:  Nat Commun       Date:  2022-03-11       Impact factor: 17.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.